Two stocks in Medical Devices
Abbott Laboratories vs Medtronic: profit, growth, debt and price compared
Medtronic is stronger on 5 of 7 figures: profit margin, debt, price for its expected profit, dividend and price trend. Abbott Laboratories is stronger on 1: sales growth.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Abbott LaboratoriesABT | MedtronicMDT | |
|---|---|---|
| Net margin | 9.8% | Stronger: 13.9% |
| Revenue growth, past year | Stronger: +14.46% | +13.73% |
| Debt to equity | 60.9% | Stronger: 55.4% |
| Forward P/E | 17.6× | Stronger: 15.7× |
| Dividend yield | 2.41% | Stronger: 2.83% |
| Analysts | Buy · 26 | Buy · 26 |
| From its 200-day average | 0.0% | Stronger: +12.5% |
Share price over the past year
- Abbott Laboratories−19.6%
- Medtronic−0.1%
18 Nov 202518 Nov 2026
Abbott Laboratories or Medtronic: which is stronger?
- MDT
Which is more profitable?
Medtronic keeps more of each sale as profit: 13.9% against 9.8%.
- ABT
Which is growing its sales faster?
Abbott Laboratories is growing its sales faster: +14.46% over the past year, against +13.73%.
- MDT
Which has borrowed less?
Medtronic has borrowed less: its debt is 55.4% of what its shareholders own, against 60.9% for Abbott Laboratories.
- MDT
Which costs less for the profit it is expected to make?
Medtronic costs less for the profit it is expected to make: 15.7× its forward earnings, against 17.6×.
- MDT
Which pays more in dividends?
Medtronic pays more back in dividends for what a share costs: 2.83% a year, against 2.41%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- MDT
Which is in the stronger price trend?
Medtronic's price is in the stronger trend: 12.5% above its 200-day average, against 0.0% above.
What each company does
ABTAbbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Reports results on 28 January 2027
MDTMedtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Reports results on 24 November 2026
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.